Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
26 juin 2024 07h00 HE
|
Lyell Immunopharma, Inc
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
Theratechnologies présente des données précliniques au congrès 2024 de l’AACR qui met en évidence la polyvalence et la flexibilité de la plateforme technologique d’oncologie SORT1+(MC)
08 avr. 2024 16h30 HE
|
Theratechnologies
Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple...
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
08 avr. 2024 16h30 HE
|
Theratechnologies
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing...
ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
25 mars 2024 09h00 HE
|
ProLynx Inc.
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial...
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
05 mars 2024 16h30 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - AstraZeneca, Daiichi Sankyo, Pfizer, OncoSec, Merck, OncoPep, Roche
28 nov. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market -...
Triple-Negative Breast Cancer Treatment Market Size to Surpass US$ 20 Billion by 2030
25 sept. 2023 14h45 HE
|
Zion Market Research
NEW YORK, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Triple-Negative Breast Cancer Treatment Market By Drug Type...
Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight
10 juil. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 10, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight The prevalence of triple-negative breast...
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
02 mai 2023 08h15 HE
|
Qualigen Therapeutics, Inc.
Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
18 avr. 2023 07h30 HE
|
Qualigen Therapeutics, Inc.
In Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen”...